INTRODUCTION
Obesity, arising from an imbalance between energy intake and energy expenditure, leads to a number of metabolic dysfunctions, including excess triglyceride (TG) synthesis and hepatic lipid accumulation. 1 There is increasing evidence linking fermentable carbohydrates to the management of appetite regulation and negative energy balance in healthy and obese subjects. [2] [3] [4] Several studies have shown that dietary supplementation of fermentable carbohydrates results in appetite suppression, reduced body adiposity and lower lipid accumulation in liver cells, as well as increased expression of anorexigenic gut hormones. 3, [5] [6] [7] [8] The consumption of fermentable carbohydrates results in the formation of short-chain fatty acids (SCFAs) mainly acetate, propionate and butyrate in the colon by microbiota. Butyrate is largely utilized as a substrate for colonocytes; propionate is taken up by the gut and mostly metabolized by the liver, whereas acetate enters the peripheral circulation. 9 It has been suggested that increased production of SCFAs may have an important role in both satiety and adipose tissue (AT) remodeling. 10 Acetate is the main SCFA found in circulation and therefore the prime candidate to induce significant metabolic modulation in peripheral tissues. There is, however, conflicting evidence regarding the mechanism of action of acetate on lipid metabolism that may arise from its short half-life combined with the nontargeted nature of oral and peripheral administration. Although some studies showed that administration of SCFAs acetate and propionate inhibit lipolysis, 11, 12 others have shown that acetate decreased fat accumulation through modification of either fatty acid oxidation 13 or fatty acid synthesis and AMP-activated protein kinase activity. 14, 15 Recently, we have shown that acetate has an important role in appetite suppression. 16 Although we have found evidence to support a central mechanism for the mode of action of acetate, less is known regarding potential peripheral mechanisms.
In order to assess the peripheral action of acetate, herein we utilize a novel nanoparticle delivery method, whereby acetate is passively targeted to the periphery. Using this method, we investigated the effects of acetate on liver lipid accumulation, inflammation and mitochondrial metabolism. Our findings suggest that the positive effects of acetate on liver lipid accumulation are as a result of mitochondrial modifications in both the liver and subcutaneous adipose tissue (SAT), leading to 'browning' of SAT and an overall improvement in metabolism and body composition in the absence of changes in calorie intake or physical activity.
MATERIALS AND METHODS

Experimental animals
All in vivo experiments were carried out in compliance with the Animals (Scientific Procedure) Act 1986. Mice were supplied by Harlan, UK and housed four per cage, in a temperature-controlled room at approximately 21-23°C with alternating 12-h periods of light and dark (light: 0700-1900 hours) in filter-topped cages with ad libitum access to water. Normal fat diet (NFD) was the RM3 diet supplemented by Special Diet Services (Essex, UK); 60% of the caloric content of the high-fat diet (HFD) was fat (EF D12402; Special Diet Services).
Chronic LIposome encapsulaTed Acetate (LITA) nanoparticle administration to C57BL/6 mice placed on a HFD or an NFD intraperitoneal (i.p.) injection of either LITA nanoparticle (n = 24) or control (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (n = 24) three times per week. Whole-body 1 H and liver 1 H magnetic resonance spectroscopy were performed prior to dietary intervention and after 4 weeks of the start of the study to calculate whole-body adiposity and intrahepatocellular lipid (IHCL) content, respectively. At the start of week 5, a fasted glucose tolerance test was performed, (n = 10-12) or animals went into Comprehensive Lab Animal Monitoring System (CLAMS, Columbus Instruments, Columbus, OH, USA) (n = 8). After week 6, animals were killed; blood samples and organs, including the liver, epididymal, mesenteric and subcutaneous fat depots were collected and stored at − 80°C for measurement of enzymes, markers and gene expression analysis. The details of all procedures are provided in the Supplementary Information.
Cell culture THLE-2 cells (ATCC CRL-2706; Manassas, VA, USA), which are derived from normal human liver cells and transformed with SV40 large T antigen were purchased from ATCC and grown in BEBM medium supplemented with BEGM Bullet Kit (Lonza, Basel, Switzerland) at 37°C with 5% CO 2 as per ATCC's instructions. A549 Parent (wild type) and rho0 (lacking mitochondrial DNA) lung cancer cells were grown in Dulbecco's Minimum Eagle's Medium supplemented with uridine only for rho0 at 37°C with 5% CO 2 as described in Lo et al. 17 Mitochondrial function of all cell types was assessed using a XF24 Analyzer (Seahorse Bioscience, Billerica, MA, USA). A detailed protocol is provided in the Supplementary Information.
Statistical analysis
All statistical analyses were performed using GraphPad Prism (GraphPad Software, San Diego, CA, USA). Data are presented as means ± s.d. except where stated as mean ± s.e.m. Statistical significance was calculated with Student's t-test or repeated-measures analysis of variance where appropriate. Significance was accepted at the level of *Po0.05, **P o 0.01, ***Po0.001. Figure S1a) nanoparticles were prepared from lipids by thin film hydration method and then employed for the functional delivery of acetate to the main organs in the periphery following i.p. administration. 16 To show that acetate is encapsulated in the liposomes, we employed the affinity of albumin to bind ions and the fact that it is nuclear magnetic resonance 'invisible'. When acetate binds to albumin, it becomes 'invisible' to nuclear magnetic resonance (Supplementary Figures  S1b and c) , but when acetate is encapsulated in the liposomes, albumin cannot bind to it and the acetate peak is still visible (Supplementary Figures S1d and e) . The concentration of acetate was similar to physiological levels; in 200 μl of LITA about 52.9 μg (4.41 mM) and the size of the liposomes were 102.3 ± 7.5 and 95.9 ± 9.0 nm for LITA and control liposomes, respectively (P = 0.6). One hundred-nm is suggested as the optimal size to create stable liposomes. 18, 19 Biodistribution to the liver, heart, muscle, spleen and lung was confirmed by histological analysis (making use of fluorescence tags, LITA-Rhd) at 2 h after administration (Supplementary Figures  S1f-j) . Extended biodistribution at 24 and 48 h after administration was assessed by magnetic resonance imaging, using a positive lipid-based contrast agent (LITA-Gd). 20 Increased uptake of LITAGd in the liver was confirmed by the expected reduction in T1 value (Supplementary Figure S1k) . No change in brain T1 was observed (Supplementary Figure S1l) . Overall, these studies confirmed that only peripheral tissues were reached by the LITA nanoparticle. This is typical for nanoparticles of this type, confirming that LITA nanoparticles do not enter the brain. Therefore, results obtained in this study would be independent of any potential appetite-suppressing effect by acetate.
RESULTS
Development of nanoparticle delivery system for acetate LITA (Supplementary
Acetate reduces whole-body and ectopic lipid accumulation with no reduction in food intake or weight gain In order to assess the effects of acetate on overall metabolism, lean 8-week-old C57BL/6 mice were put on NFD or HFD and were administered i.p. with control or LITA nanoparticles three times per week for 6 weeks. Acetate administration in LITA nanoparticles reduced whole-body adiposity significantly in HFD-fed mice (P o 0.05), with similar trend in NFD-fed mice (P o0.08) (Figures 1a and b) . No change was observed in the daily food intake of both groups, even so the NFD group showed an overall weight gain with LITA treatment (Supplementary Figures S2a-d) . Furthermore, lean mass was significantly increased in the HFD-fed group with LITA treatment (P o 0.05), with a similar trend observed in the NFD-fed group (P = 0.07) (Figures 1c and d) . Importantly, LITA treatment in both groups led to a reduced accumulation of IHCL in both groups (P o0.05, Figures Acetate improves liver function LITA treatment resulted in a reduction in aspartate aminotransferase (AST) and alkaline phosphatase (ALP) serum levels in the HFD group, suggesting an improvement in liver function (P o 0.05, Figure 2a ). Similarly, there was a reduction in serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) concentrations in HFDfed mice treated with LITA, though this did not reach significance (P o 0.07, Figure 2b ). This was associated with a reduction in TNF-α expression in both the liver (P o 0.01) and SAT (P o 0.001) (Figure 2c ). No change was observed in liver function enzymes of NFD mice treated with LITA, but a significantly lower serum concentration of TNF-α (P o0.01) and reduced expression of TNF-α in the liver (P o 0.05) was observed (Figures 2d and e). These changes are significant as pro-inflammatory cytokines such as TNF-α and IL-6 are believed to trigger inflammation in the liver following lipid accumulation, leading to liver fibrosis. 21 No changes were observed in monocyte chemoattractant protein-1 or resistin in both cohorts (Figures 2f and g ).
Glucose metabolism is altered by acetate No change was observed in the recovery of blood glucose to baseline level after glucose tolerance test in NFD (Figures 3a and  b) or HFD (Figures 3c and d) . In the NFD cohort, homeostatic model assessment of insulin resistance was significantly reduced with acetate treatment (Figures 3e and g ). In the HFD cohort, the fasted level of glucose dropped less, with no change in fasted insulin, and fed insulin levels were lower (P o0.05), with no change in fed glucose (Figures 3f and g ). The gene expression of glucose transporter 2 (GLUT2) in the HFD cohort was significantly reduced with LITA treatment (P o 0.01, Figure 3h ). Serum glucagon levels showed a significant increase with LITA administration compared with control in HFD-fed mice (P o0.05, Figure 2g ), possibly owing to reduced insulin levels. Acetate reduces AT lipolysis, circulating free fatty acid (FFA) levels and de novo lipogenesis in the liver In HFD-fed mice, the gene expression of adipose tissue TG lipase (ATGL), which breaks down TG into diacylglycerols and FFAs, 22 was reduced with LITA (Figure 4a ), correlating with reduced circulating levels of serum FFAs (P o0.05, Figure 4b) . Similarly, mRNA expression of genes in the liver involved in de novo lipogenesis, namely, sterol regulatory element-binding protein 1 (SREBP1), fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC), were significantly reduced following LITA treatment (P o 0.01, Figure 4c ). These reductions in circulating serum FFAs, owing to reduced SAT-based lipolysis, together with reductions in de novo lipogenesis could certainly offer explanation for the observed reduction in IHCL with LITA treatment. These effects appear to be balanced by LITA treatment-induced reductions in fatty acid oxidation and very-low-density lipoprotein (VLDL) export compared with control, as reflected by downregulation in the expression of fatty acid oxidation genes carnitine palmitoyltransferase I (CPT1, P o0.01) and acyl-CoA oxidase 1 (ACOX, P o0.05) and VLDL synthesis (P o0.001). These latter data are in line with reduced FFAs reaching the liver.
Acetate improves liver mitochondrial function and increases adenosine triphosphate (ATP) production Impaired mitochondrial metabolism is an underlining cause for a number of diseases, including fatty liver. 23 Initially, liver mitochondria were assessed using transmission electron microscopy (TEM). No change was observed in the number of mitochondria (Figures 5a and b) while genes involved in the mitochondrial biogenesis remained unaffected (Figure 5e ). However, a trend toward increasing numbers of cristae per mitochondria was Figure 6 . Acetate increases heat dissipation through browning of SAT. Heat produced measured by CLAMS of control and LITA-administered mice fed with HFD shown as time course (a) and sum of light and dark phases (b) (n = 8). Heat produced measured by CLAMS of control and LITA-administered mice fed with NFD shown as time course (c) and sum of light and dark phases (d) (n = 8). Fold change in LITA mRNA expression of BAT signature genes compared with control (represented by dotted line) in SAT of mice fed with HFD (n = 6) (e) and of mice fed with NFD (n = 6) (f) and in BAT of mice fed with HFD (g). (h) Weight of BAT tissue dissected from the NFD-and HFD-fed mice (n = 12). All data are shown as mean ± s.d., except from panels (a) and (c) which are shown as mean ± s.e.m., *Po 0.05, **P o0.01 and ***P o0.001.
observed (P o0.07, Figures 5c and d) . As cristae are the sites for electron transport chain, protein expression of these complexes was investigated. Significant increases in the expression of complexes III, IV and V were detected (P o0.05, P o 0.01 and P o0.001, respectively, Figures 5f and h). Moreover, there was a significant reduction in the expression levels of uncoupling protein 2 (UCP2, P o0.05, Figure 5e ), suggesting a less 'leaky' mitochondrial membrane, providing more electrons for the electron transport chain and increased ATP production. In order to further assess the potential effect of acetate on ATP production, immortal non-cancerous hepatocytes (THLE-2, an in vitro model for normal liver cells) were treated with acetate and oxygen consumption rate was monitored using a XF-analyzer. Basal respiration and ATP production were significantly increased by acetate. (Figure 5g ).
Acetate increases thermogenic capacity through 'browning' of white adipose tissue (WAT) HFD-and NFD-fed mice treated with LITA or its control counterpart underwent physiological analysis by CLAMS. Acetate administration by LITA nanoparticle increased heat production in both HFD (P o0.01, Figures 6a and b) and NFD (P o0.05, Figures 6c and d) fed mice. Recently, it has been shown that WAT depots can be 'browned' by activators, such as cold. [24] [25] [26] [27] 'Beige' or 'brite' adipocytes have more abundant mitochondria compared with white adipocytes, thus increasing thermogenic potential. 28 As we observed increased thermogenic output in the LITA-treated animals, gene expression of UCP1 in SAT was investigated. In the HFD cohort, UCP1 expression was significantly increased (P o 0.001, Figure 6e ). We then went on to assess peroxisome proliferator activated receptor gamma coactivator 1 alpha (PGC1α) and PR domain containing 16 (PRDM16) to confirm the possibility of 'browning' of WAT, as both are involved in the differentiation of brown-like adipocytes. 25, 29 PRDM16 was significantly increased (P o 0.001), while PGC1α showed a similar trend (Figure 6e ). In the NFD cohort, a significant increase in PRDM16 (P o 0.001) expression was also observed, whereas UCP1 and PGC1α expression levels remained unchanged (Figure 6f ). These changes occurred independent of changes in size or UCP1 expression of brown adipose tissue (BAT, the AT depot behind the neck of mice), the main site for heat production (Figures 6g and h) . In both cohorts VO 2 and VCO 2 trended to be higher but did not reach significance and physical activity was unaffected by LITA treatment (Supplementary Figures S4 and S5 , NFD and HFD, respectively).
Positive effects of acetate are lost in the presence of dysfunctional mitochondria Rho0 cells, derived from A549 lung cancer cells, lack mitochondrial DNA 17 and are deficient in proteins of respiratory complexes I, III, IV and V 30 (Supplementary Figure S6a) . Rho0 cells and wild-type A549 cells (parent) were treated with 1 mM acetate leading to increased ATP-linked respiration in 'parent' cells (P = 0.06), whereas this effect was absent in Rho0 cells (P o0.4, Supplementary  Figures S6b and c) . In order to confirm in vivo that the beneficial effects of acetate on adiposity and inflammation was mediated by mitochondria, a group of mice were put on methionine cholinedeficient diet (MCD) and treated with LITA versus control nanoparticles. Mice on MCD have been previously shown to have impaired mitochondrial function and increased liver inflammation. 31 No reversal in liver fat accumulation or body adiposity was observed following LITA treatment (Supplementary Figure S6d) . In addition, serum inflammatory markers remained unchanged by LITA treatment (Supplementary Figure S6e) , confirming that acetate requires functional mitochondria to exert its beneficial effects.
DISCUSSION
In this study, we make novel mechanistic insights into the peripheral effects of the SCFA acetate, following its delivery by a nanoparticle-mediated system. The beneficial peripheral phenotypic effects of acetate are clearly independent of its effect on the brain, where it is also known to be active. 16 Our results reveal for the first time that acetate stimulates a number of autonomous mechanisms in different peripheral tissues. In the liver, it reduces fat deposition through a reduction in circulating FFAs and de novo lipogenesis and an increase in mitochondrial efficiency, while in adipose tissue it induces 'browning', leading to a contraction in body adiposity.
Peripheral administration (oral/i.p.) of acetate has been previously shown to result in non-targeted uptake, rapid clearance from the circulation and reduced pH. 32 Lipid-based nanoparticles such as LITA can be used to target drugs to tissues 33 and have been employed in our laboratory to mediate functional siRNA delivery, 34 as well as magnetic resonance imaging contrast agents, to tumors. 18, 20 By adopting this methodology, we passively target the liposomes to peripheral tissues and increase the bioavailability of acetate. This enables in vivo studies of the mechanism underlying the action of individual SCFA (separately or in combination) to be undertaken in a more controlled manner. This is important as recent work suggest that propionate and butyrate have very distinctive metabolic effects. 35 Furthermore, our methodology allows for a separation of peripheral and central effects of acetate.
Our data herein shows that acetate reduces whole-body fat without a decrease in caloric intake or weight gain. Previously, Yamashita et al.
14 have reported reduced food intake and weight in mice that received acetate orally; however, like others, their experimental design made it impossible to disassociate central from peripheral effects. Indeed, we recently demonstrated the central mechanism underpinning the appetite-suppressing effect of acetate and how this effect is lost when acetate is encapsulated in liposomes. 16 Thus, the use of a lipid-based nanoparticle delivery system in our study enabled us to investigate the effect of acetate independent of its appetite-suppressing action, which partly explain the lack of weight change reported by others. 13, 14 Furthermore, the decrease in adiposity observed in our study was accompanied by an increase in lean mass, which would in turn balance changes in overall weight.
We have also observed that acetate treatment reduces ectopic fat accumulation first by reducing lipolysis 11 through a reduction in the expression of ATGL in SAT, 22 which correlates with the observed reduction in serum FFA concentration. Reduced circulating FFAs then ameliorate hepatic exposure resulting in reduced TG synthesis and deposition in the liver. This finding is supported by a recent report that FFA is the main mechanism responsible for TG synthesis in the liver. 36 Furthermore, we also see a reduction in insulin, which is known to regulate de novo lipogenesis in the liver through its action on SREBP1. 37 Suppression of SREBP1 expression and lowering glucose uptake by the liver, shown by reduced GLUT2 expression, is known to reduce de novo lipogenesis. 38 Together with SREBP1, the expression of downstream genes FASN and ACC was concomitantly reduced. Recent studies have suggested that acetate in the liver is converted into acetyl-coA in the cytoplasm through ACSS2 and synthesized to long chain fatty acids. 39 However, in our study we show that chronic treatment with acetate suppresses the expression of ACSS2 together with lipid synthesis and it increases the expression of oxidative phosphorylation (OXPHOS) proteins, suggesting improved mitochondrial metabolism.
Glucose metabolism was also affected by acetate treatment. Reduced insulin and maintained glucose concentrations in fed state suggest that acetate improves insulin sensitivity. In the fasted state, the drop in blood glucose levels in mice treated with LITA nanoparticles was not as pronounced as in mice treated with control nanoparticles. This is contrary to findings of Yamashita et al.
14 who reported a reduction in fasting glucose with acetate treatment, although their use of a diabetic rat model may account for these differences. In addition, the observed reduction in the expression of GLUT2 following LITA treatment, together with reduced serum insulin and a less enhanced drop in blood glucose in the fasted state, are consistent with changes in the liver fuel source away from glucose. This is in agreement with the Randle hypothesis 40 that links fatty acids to inhibition of glucose oxidation.
Mitochondria, which are at the center of fatty acid metabolism and OXPHOS, have a key role in hepatocyte function. 23 Mitochondrial dysfunction is also closely linked to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). 41 Furthermore, increased UCP2 expression has been associated with non-alcoholic steatohepatitis (NASH) development 42 and lipid accumulation reduces the efficiency of OXPHOS in the liver. 43 In our study, we have observed reduced UCP2 expression in LITA-treated mice together with increased protein expression of OXPHOS complexes. In immortal THLE-2 cells, ATP-linked respiration is increased with acetate treatment. Furthermore, when mitochondrial function is impaired (in Rho0 cells, by deletion of mitochondrial DNA; and in vivo, by feeding a MCD), ATP production and liver fat accumulation remain unaffected by LITA treatment. This is a strong evidence that enhancement in mitochondrial function is pivotal to the prevention of NAFLD by acetate. Although in vitro lung cancer cells were used instead of liver cells, A549 cells still carry out beta-oxidation, 44 which makes them a good model for investigating the effect of acetate on mitochondria function.
Mitochondrial modulations in adipose tissue may also explain how acetate reduces whole-body adiposity without appetite suppression. Acetate treatment causes increased thermogenic capacity in mice, independent of BAT, through the process of 'browning' of WAT. It has been recently shown that heat dissipation by browning of WAT has a greater role in the management of obesity than the BAT itself. 45, 46 This is in line with reports that mice lacking the mitochondrial acetyl-CoA synthatase 1 (ACSS1) are hypothermic when fasted. 47 However, it is not clear whether the 'browning process' in this study is a direct effect of acetate or owing to the effects of reduced overall adiposity, which may in turn lead to 'browning' of WAT. 48 Similarly, the observed increase in lean mass may contribute to overall energy expenditure and reduce AT content. 49 Moreover, inhibition of gluconeogenesis has been recently linked with increased energy expenditure. 50 As acetate appears to reduce liver glucose production, this should also be investigated as a potential route of action.
The overall benefits of acetate on the liver are strongly supported by reduced expression of TNF-α and lower serum TNF-α and IL6, suggesting less basal inflammation. 51, 52 In addition, the reduction in serum AST and ALP levels, which are normally associated with NAFLD, 53 are a strong indicator of reduced hepatocellular damage. Although these changes were observed at an early stage of high fat feeding, they do suggest that LITA treatment may help to prevent the onset of NAFLD. In fact, when mice were fed with HFD for 5 weeks prior to treatment with LITA, significant reduction in IHCL level was observed. Furthermore, reduced levels of inflammation, serum insulin, serum FFAs and liver fat are all implicated in minimizing progression toward tumorigenesis. 54, 55 The effect of acetate on tumorigenesis should also be investigated.
In conclusion, our study demonstrates significant peripheral effects of acetate on lipid metabolism, independent of its central action. Acetate administration via lipid-based nanoparticle reduces ectopic lipid accumulation through suppression of lipolysis in adipose tissue and by reducing de novo lipogenesis in the liver. We have demonstrated for the first time that acetate modulates mitochondrial function in the liver, increasing OXPHOS and ATP production, and in the SAT increasing thermogenic activity. Our findings show that acetate has the potential to be a novel and effective treatment for obesity and fatty liver disease.
